These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34192267)

  • 21. Antagonism of Type I Interferon by Severe Acute Respiratory Syndrome Coronavirus 2.
    Xia H; Shi PY
    J Interferon Cytokine Res; 2020 Dec; 40(12):543-548. PubMed ID: 33337934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nucleic Acid-Sensing Pathways During SARS-CoV-2 Infection: Expectations versus Reality.
    Mdkhana B; Saheb Sharif-Askari N; Ramakrishnan RK; Goel S; Hamid Q; Halwani R
    J Inflamm Res; 2021; 14():199-216. PubMed ID: 33531826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune evasion of SARS-CoV-2 from interferon antiviral system.
    Min YQ; Huang M; Sun X; Deng F; Wang H; Ning YJ
    Comput Struct Biotechnol J; 2021; 19():4217-4225. PubMed ID: 34336145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness?
    Sacchi A; Giannessi F; Sabatini A; Percario ZA; Affabris E
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Innate immune sensing of coronavirus and viral evasion strategies.
    Kasuga Y; Zhu B; Jang KJ; Yoo JS
    Exp Mol Med; 2021 May; 53(5):723-736. PubMed ID: 33953325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Integral Membrane Protein ZMPSTE24 Protects Cells from SARS-CoV-2 Spike-Mediated Pseudovirus Infection and Syncytia Formation.
    Shilagardi K; Spear ED; Abraham R; Griffin DE; Michaelis S
    mBio; 2022 Oct; 13(5):e0254322. PubMed ID: 36197088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Covid-19: Perspectives on Innate Immune Evasion.
    Taefehshokr N; Taefehshokr S; Hemmat N; Heit B
    Front Immunol; 2020; 11():580641. PubMed ID: 33101306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
    Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
    Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant.
    Zhou H; Møhlenberg M; Thakor JC; Tuli HS; Wang P; Assaraf YG; Dhama K; Jiang S
    Clin Microbiol Rev; 2022 Sep; 35(3):e0001422. PubMed ID: 35862736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 ORF6 protein does not antagonize interferon signaling in respiratory epithelial Calu-3 cells during infection.
    Li M; Ayyanathan K; Dittmar M; Miller J; Tapescu I; Lee JS; McGrath ME; Xue Y; Vashee S; Schultz DC; Frieman MB; Cherry S
    mBio; 2023 Aug; 14(4):e0119423. PubMed ID: 37377442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inactivating Three Interferon Antagonists Attenuates Pathogenesis of an Enteric Coronavirus.
    Deng X; Buckley AC; Pillatzki A; Lager KM; Faaberg KS; Baker SC
    J Virol; 2020 Aug; 94(17):. PubMed ID: 32554697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective.
    Alnefaie A; Albogami S
    Saudi Pharm J; 2020 Nov; 28(11):1333-1352. PubMed ID: 32905015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insight into the emerging role of SARS-CoV-2 nonstructural and accessory proteins in modulation of multiple mechanisms of host innate defense.
    Abdalla AE; Xie J; Junaid K; Younas S; Elsaman T; Abosalif KOA; Alameen AAM; Mahjoob MO; Elamir MYM; Ejaz H
    Bosn J Basic Med Sci; 2021 Oct; 21(5):515-527. PubMed ID: 33714258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The SARS-Coronavirus Infection Cycle: A Survey of Viral Membrane Proteins, Their Functional Interactions and Pathogenesis.
    Wong NA; Saier MH
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33525632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evasion of Type I Interferon by SARS-CoV-2.
    Xia H; Cao Z; Xie X; Zhang X; Chen JY; Wang H; Menachery VD; Rajsbaum R; Shi PY
    Cell Rep; 2020 Oct; 33(1):108234. PubMed ID: 32979938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
    Gong W; Parkkila S; Wu X; Aspatwar A
    Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antagonism of dsRNA-Induced Innate Immune Pathways by NS4a and NS4b Accessory Proteins during MERS Coronavirus Infection.
    Comar CE; Goldstein SA; Li Y; Yount B; Baric RS; Weiss SR
    mBio; 2019 Mar; 10(2):. PubMed ID: 30914508
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.